MedTrace Logo

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

NCT04676997 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-12-21

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy, safety and tolerability of Camrelizumab Combination With Nab-Paclitaxel and Epirubicin as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Conditions

Interventions

BIOLOGICAL

Camrelizumab

200mg on days1,15 of Cycles 1-4 (Q2W); IV infusion. 200mg on day 1 of Cycles 5-8 (Q2W); IV infusion.

DRUG

Nab paclitaxel

125 mg/m² on day 1, 8 and 15 of Cycles 1-4 (QW 3/4); IV infusion.

DRUG

Epirubicin

90 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.

DRUG

Cyclophosphamide

600 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    collaborator INDUSTRY

  • Shandong Cancer Hospital and Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-20
Primary Completion
2021-07-30
Completion
2024-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04676997 on ClinicalTrials.gov